Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $466.9 million.

  • Dexcom's Cost of Revenue rose 201.01% to $466.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year increase of 1663.53%. This contributed to the annual value of $1.9 billion for FY2025, which is 1663.53% up from last year.
  • Latest data reveals that Dexcom reported Cost of Revenue of $466.9 million as of Q4 2025, which was up 201.01% from $477.9 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Cost of Revenue ranged from a high of $477.9 million in Q3 2025 and a low of $161.1 million during Q1 2021
  • Over the past 5 years, Dexcom's median Cost of Revenue value was $338.3 million (recorded in 2023), while the average stood at $329.2 million.
  • As far as peak fluctuations go, Dexcom's Cost of Revenue surged by 4320.3% in 2022, and later soared by 201.01% in 2025.
  • Over the past 5 years, Dexcom's Cost of Revenue (Quarter) stood at $225.6 million in 2021, then grew by 21.41% to $273.9 million in 2022, then soared by 37.97% to $377.9 million in 2023, then increased by 21.12% to $457.7 million in 2024, then grew by 2.01% to $466.9 million in 2025.
  • Its Cost of Revenue stands at $466.9 million for Q4 2025, versus $477.9 million for Q3 2025 and $468.3 million for Q2 2025.